Clinical significance of IGFBP2 and ERK1/2 expression in clear cell renal cell carcinoma

doi:10.3877/cma.j.issn.2095-655X.2022.01.009

Abstract

Abstract:

Objective

To explore the expression and clinical significance of IGFBP2 and ERK1/2 in the clear cell renal cell carcinoma (ccRCC).

Methods

Clinical data of 174 ccRCC patients who underwent surgical treatment in the Department of Urology, Affiliated Hospital of Jining Medical University from June 2017 to April 2019 were selected, and the blood samples of 30 healthy individuals were selected in the Health Examination Center during the same period. The expressions of IGFBP2 and ERK1/2 in ccRCC and adjacent (2 cm from the edge of the tumor) tissues were assessed by immunohistochemistry and the correlation with clinical stage, histological grade and tumour size was analyzed. Serum levels of IGFBP2, ERK1 and ERK2 were also measured by ELISA in ccRCC patients and healthy controls.

Results

The positive ratios of IGFBP2 and ERK1/2 expression in ccRCC tissues (87.93%, 80.46%) were higher than those in precancerous tissues (6.67%, 10.00%), all of which were significantly different (χ²=92.59, 65.87, all P<0.01). The positive ratios of IGFBP2 and ERK1/2 expression in tumors larger than 4 cm were higher than those in tumors smaller than 4 cm, all of which were statistically significant (χ²=7.81, 13.02, all P<0.05). There were no significant differences in the expression of IGFBP2 and ERK1/2 at patients′ age (χ²=0.78, 0.60), gender (χ²=0.05, 1.33), or tumor location (χ²=0.96, 0.57) (all P>0.05). The positive expression rates of IGFBP2 and ERK1/2 increased with higher clinical stage and histological grade, and were statistically significant between groups in different grades (Z=-8.17, -3.80, all P<0.05) and different stages(Z=-5.63, -9.94, all P<0.05). The expression of IGFBP2 was significantly positively correlated with ERK1/2 in ccRCC tissues (r=0.32, P<0.05). ELISA showed that IGFBP2, ERK1, ERK2 were significantly increased in ccRCC patients [(858.33±132.89)μg/L, (12.49±1.22)μg/L, (153.61±33.37)ng/L] compared with healthy controls [(267.65±86.56)μg/L, (8.69±1.80)μg/L, (105.63±12.03)ng/L], all of which were significantly different (t=11.78, 5.53, 4.28, all P<0.05).

Conclusion

The expressions of IGFBP2 and ERK1/2 are elevated in serum and tumor tissues in ccRCC patients, and their positive expressions in tumor tissues are correlated with histological grade, clinical stage, and tumor size, the histological grade, later clinical stage, and larger tumor volume, the higher the positive expression rates of both suggesting that both may play a synergistic role in tumor progression.

Key words: Carcinoma, renal cell, Insulin-like growth factor binding proteins 2, Extracellular regulated protein kinase 1/2, Immunohistochemistry, Enzyme-linked immunosorbent assay

Jianzhi Lyu, Jinghe Cao, Huan Liu, Xinzhe Wang, Susu Shi, Haizhou Zhu. Clinical significance of IGFBP2 and ERK1/2 expression in clear cell renal cell carcinoma[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(01): 42-47.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.01.009

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I01/42

Figures/Tables 5

References 30

[1]	Siegel RL, Miller KD, Fuchs HE，et al.Cancer statistics，2021[J]．CA Cancer J Clin，2021，71(1): 7-33.DOI: 10.3322/caac.21695.
[2]	Capitanio U, Bensalah K, Bex A，et al.Epidemiology of renal cell carcinoma[J]．Eur Urol，2019，75(1): 74-84.DOI: 10.1016/j.eururo.2018.08.036.
[3]	Nabi S, Kessler ER, Bernard B，et al.Renal cell carcinoma：a review of biology and pathophysiology [J]．F1000Res，2018(7): 307.DOI: 10.12688/f1000research.13179.1.
[4]	Fürstenberger G, Senn HJ.Insulin-like growth factors and cancer[J]．Lancet Oncol，2002，3(5): 298-302.DOI: 10.1016/s1470-2045(02)00731-3.
[5]	高松，郝继辉．胰岛素样生长因子结合蛋白2在肿瘤恶性生物学行为中的作用及其临床应用 [J]．中国肿瘤临床，2017，(16): 826-830.DOI: 10.3969/j.issn.1000-8179.2017.16.499.
[6]	Hur H, Yu EJ, Ham IH，et al.Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients [J]．Oncotarget，2017，8(7): 10994-11003.DOI: 10.18632/oncotarget.14202.
[7]	Zhu H, Zhang Y, Geng Y, et al. IGFBP2 promotes the EMT of colorectal cancer cells by regulating E-cadherin expression [J]．Int J Clin Exp Pathol，2019，12(7): 2559-2565.
[8]	Verma BK, Kondaiah P．Regulation of beta-catenin by IGFBP2 and its cytoplasmic actions in glioma[J]．J Neurooncol，2020，149(2): 209-217.DOI: 10.1007/s11060-020-03596-4.
[9]	Biernacka KM, Uzon CC, Zeng L，et al.Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2[J]．Endocr Relat Cancer，2013，20(5): 741-751.DOI: 10.1530/ERC-13-0077.
[10]	Fan Z, Soder S, Oehler S，et al.Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage[J]．Am J Pathol，2007，171(3): 938-946.DOI: 10.2353/ajpath.2007.061083.
[11]	Wang C, Gao C, Meng K，et al.Human adipocytes stimulate invasion of breast cancer MCF-7 cells by secreting IGFBP-2 [J]．PLoS One，2015，10(3): e0119348.DOI: 10.1371/journal.pone.0119348.
[12]	Kim EK, Choi EJ.Pathological roles of MAPK signaling pathways in human diseases[J]．Biochim Biophys Acta，2010，1802(4): 396-405.DOI: 10.1016/j.bbadis.2009.12.009.
[13]	黄健．中国泌尿外科和男科疾病诊断治疗指南2019版[M]．北京：科学出版社，2020：1-7.
[14]	Mahul B, Amin , Stephen B，et al.AJCC cancer staging manual[M]．Berlin：Springer International Publishing，2017.
[15]	Delahunt B, Sika-Paotonu D, Bethwaite PB，et al.Grading of clear cell renal cell carcinoma should be based on nucleolar prominence[J]．Am J Surg Pathol，2011，35(8): 1134-1139.DOI: 10.1097/PAS.0b013e318220697f.
[16]	Moch H, Cubilla AL, Humphrey PA，et al.The 2016 WHO classification of tumours of the urinary system and male genital organs-part B：Prostate and bladder tumours [J]．Eur Urol，2016，70(1): 106-119.DOI: 10.1016/j.eururo.
[17]	高松．IGFBP2调节胰腺癌转移及侵袭的机制及其临床意义[D]．天津：天津医科大学，2015.
[18]	Pollak M. Insulin and insulin-like growth factor signalling in neoplasia[J]．Nat Rev Cancer，2008，8(12): 915-928.DOI: 10.1038/nrc2536.
[19]	Cao Y, Nimptsch K, Shui IM，et al.Prediagnostic plasma IGFBP-1，IGF-1 and risk of prostate cancer [J]．Int J Cancer，2015，136(10): 2418-2426.DOI: 10.1002/ijc.29295.
[20]	Zhang W, Wang H, Song SW，et al.Insulin-like growth factor binding protein 2 gene expression microarrays and the hypothesis-generation paradigm [J]．Brain Pathol，2002，12(1): 87-94.DOI: 10.1111/j.1750-3639.2002.tb00425.x.
[21]	Elmlinger MW, Deininger MH, Schuett BS，et al.In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade [J]．Endocrinology，2001，142(4): 1652-1658.DOI: 10.1210/endo.142.4.8084.
[22]	Liou JM, Shun CT, Liang JT，et al.Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer [J]．J Clin Endocrinol Metab，2010，95(4): 1717-1725.DOI: 10.1210/jc.2009-2668.
[23]	Yao X, Wang Y, Duan Y，et al.IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway [J]．Cancer Lett，2018(432): 38-46.DOI: 10.1016/j.canlet.2018.06.008.
[24]	程杨，袁金，聂妙玲，等．VEGF-C激活ERK1/2上调Slug蛋白表达促进宫颈癌细胞侵袭[J]．热带医学杂志，2018，18(7): 846-849，868.DOI: 10.3969/j.issn.1672-3619.2018.07.003.
[25]	王艳军，王高雄，黄天从，等．高迁移率族蛋白1通过调控Erk1/2、Cyclin D1及MMP14蛋白促进肝内胆管细胞癌进展[J]．第三军医大学学报，2019，41(5): 430-436.DOI: 10.16016/j.1000-5404.201810003.
[26]	Zou S, Xu Y, Chen X, et al. DNA polymerase iota (Pol iota) promotes the migration and invasion of breast cancer cell via EGFR-ERK-mediated epithelial to mesenchymal transition[J]．Cancer Biomark，2019，24(3): 363-370.DOI: 10.3233/CBM-181516.
[27]	林玩福．基于IGFBP2信号通路探讨解毒方对肝癌的增殖及迁移侵袭的抑制效应及作用机制 [D]．上海：中国人民解放军海军军医大学，2019.
[28]	李峰，赵涛，邵继春．细胞外信号调节激酶1/2在肾癌中的表达及临床意义[J]．川北医学院学报，2021，36(3): 288-291.DOI: 10.3969/j.issn.1005-3697.2021.03.04.
[29]	朱汝健. CEACAM6通过调控ERK/AKT信号通路促进肾癌细胞增殖和迁移的研究[D]．南京：南京医科大学，2020.
[30]	Lee HJ, Kim DI, Kang GH，et al.Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma[J]．Urology，2009，73(2): 394-399.DOI: 10.1016/j.urology.2008.08.472.

组别	例数	IGFBP2		χ²值	P值	ERK1/2		χ²值	P值
组别	例数	阳性	阴性	阳性	阴性
ccRCC组织组	174	153(87.93)	21(12.07)	92.59	<0.01	140(80.46)	34(19.54)	65.87	<0.01
癌旁组织组	30	2(6.67)	28(93.33)	92.59	<0.01	3(10.00)	27(90.00)	65.87	<0.01

组别	例数	IGFBP2		χ²值	P值	ERK1/2		χ²值	P值
组别	例数	阳性	阴性	阳性	阴性
ccRCC组织组	174	153(87.93)	21(12.07)	92.59	<0.01	140(80.46)	34(19.54)	65.87	<0.01
癌旁组织组	30	2(6.67)	28(93.33)	92.59	<0.01	3(10.00)	27(90.00)	65.87	<0.01

Please choose a citation manager

Content to export